ArticleFrontiers in pharmacology2023

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).

Si Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.